Young Investigator Awards

Twelve Young Investigator Awards, worth €1500 each, are awarded to researchers who submit abstracts (basic or clinical) to the annual European Congress of Endocrinology.

Application

Applicants must indicate on the abstract form whether they wish to be considered for an ESE Young Investigator Award.

Eligibility

Successful applicants must be within 10 years post-PhD or MD and a member of ESE at the time of the meeting. 

Evaluation

The awards are based on the achieved abstract scores, as determined by the ECE abstract review committee; the final decision is made by the ECE Programme Organising Committee.

2019 Winners

• Elizabeth Baranowski: Steroid Metabolomics: A Rapid Computational Approach for Accurate Differentiation of Inborn Disorders of Steroidogenesis.
• Alexandre Buffet: Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma
• Ashley Castellanos-Jankiewicz: Role of hypothalamic bile acid-TGR5 signaling in the regulation of energy balance
• Chiranjit Ghosh: Identification of oxygen-18 isotope of breath carbon dioxide as a non-invasive marker to distinguish type 1 and type 2 diabetes
• Juan Jiménez-Vacas: SF3B1 as novel target for the treatment of multiple endocrine-related cancers
• Blerim Mujaj: Serum insulin levels are associated with vulnerable plaque components in the carotid artery
• Mario Neou: Pan-genomic classification of Pituitary Adenomas
• Sergio Pedraza-Arévalo: The splicing factor NOVA1 is overexpressed in pancreatic neuroendocrine tumors and related to increased aggressiveness and malignancy
• Juan Roa Rivas: Conditional ablation of AMP-Activated Protein Kinase (AMPK) in GnRH Neurons Reveals Specific Roles in Reproductive and Metabolic Homeostasis
• Prudencio Sáez Martínez: Neuronostatin and GPR107 system: a novel therapeutic circuit in Prostate Cancer
• Ioana Simona Chisalita: Association of MR-proANP with cardiovascular risk factors in middle aged patients with diabetes mellitus type 2 and non-diabetic controls
• Volha Zhukouskaya: Higher dose of Burosumab is needed for treatment of children with severe forms of X-linked Hypophosphatemia